VASOTEC Drug Patent Profile

When do Vasotec patents expire, and what generic alternatives are available?

Vasotec is a drug marketed by Biovail Labs Intl and Bausch and is included in two NDAs.

The generic ingredient in VASOTEC is enalapril maleate. There are twenty-seven drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the enalapril maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vasotec

A generic version of VASOTEC was approved as enalapril maleate by HERITAGE PHARMA on August 22^nd, 2000.

Summary for VASOTEC

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	8
Drug Prices:	Drug price information for VASOTEC
What excipients (inactive ingredients) are in VASOTEC?	VASOTEC excipients list
DailyMed Link:	VASOTEC at DailyMed

See drug prices for VASOTEC

See drug sales revenues for VASOTEC

Recent Clinical Trials for VASOTEC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Wisconsin, Madison	Phase 4
Novartis Pharmaceuticals	Phase 4
Brigham and Women's Hospital	Phase 4

See all VASOTEC clinical trials

Pharmacology for VASOTEC

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Decreased Blood Pressure

US Patents and Regulatory Information for VASOTEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biovail Labs Intl	VASOTEC	enalaprilat	INJECTABLE;INJECTION	019309-001	Feb 9, 1988		DISCN	Yes	No
Bausch	VASOTEC	enalapril maleate	TABLET;ORAL	018998-002	Dec 24, 1985	AB	RX	Yes	No
Bausch	VASOTEC	enalapril maleate	TABLET;ORAL	018998-005	Jul 26, 1988	AB	RX	Yes	No
Bausch	VASOTEC	enalapril maleate	TABLET;ORAL	018998-001	Dec 24, 1985	AB	RX	Yes	No
Bausch	VASOTEC	enalapril maleate	TABLET;ORAL	018998-003	Dec 24, 1985	AB	RX	Yes	Yes

EU/EMA Drug Approvals for VASOTEC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Proveca Pharma Limited	Aqumeldi	Enalapril maleate	EMEA/H/C/005731Treatment of heart failure.	Authorised	no	no	no	2023-11-15

International Patents for VASOTEC

See the table below for patents covering VASOTEC around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	231971	PROCEDIMIENTO PARA PREPARAR N-1(S)-ETOXICARBONIL(O CARBOXI)-3-FENILPROPIL-L-ALANIL-L-PROLINAS UTILES COMO ANTIHIPERTENSIVOS
Austria	6503
Australia	530380
Australia	5346179
Bosnia and Herzegovina	98220
Bulgaria	38787	METHOD FOR PREPARING CARBOXYALKYL DIPEPTIDES
Bulgaria	39293	METHOD FOR PREPARING CARBOXYALKYL DIPEPTIDES

VASOTEC (benazepril) market dynamics and financial trajectory

Last updated: April 23, 2026

What is VASOTEC and how is it positioned commercially?

VASOTEC is the brand name for benazepril, an ACE inhibitor used to treat hypertension and heart failure. In most markets, benazepril’s commercial profile is dominated by the shift from originator-brand to generic substitution, with VASOTEC’s sales concentrated in markets and channels where patent protection, switching costs, and formulary position still support brand premiums.

Commercial base case

• Drug class: ACE inhibitor
• Active ingredient: benazepril (HCl)
• Typical use areas: hypertension; heart failure
• Market structure pressure: prolonged exposure to generic entry and therapeutic substitution after loss of exclusivity.

What drives demand for benazepril and what restrains it?

Demand drivers

1. ACE inhibitor adoption: ACE inhibitors remain standard-of-care for hypertension and heart failure, sustaining baseline demand for the molecule even as specific brands cycle.
2. Formulary coverage: When benazepril is on formularies at tier levels that reduce patient co-pays, volume persists even with multiple equivalent products.
3. Prescriber familiarity: Long-established prescribing patterns can slow switching away from certain branded SKUs in institutional settings.

Restraints

1. Generic price compression: Post-exclusivity, generics typically capture most incremental volume, forcing brand price and revenue down.
2. Payer steerage: Formularies, pharmacy benefit managers, and step therapy policies increasingly favor lowest-cost alternatives.
3. Channel inventory and contracting: Brand economics degrade when contracts shift to multi-source competitive bidding.

How does the market typically move for VASOTEC across time?

Trajectory pattern

VASOTEC’s financial trajectory in most jurisdictions typically follows a predictable curve once generic benazepril penetrates:

• Early exclusivity period: brand pricing power and higher net sales per unit.
• Mid-transition: payer contracting and generic switching reduce share.
• Later period: brand becomes a smaller share contributor, with remaining sales tied to localized formulary positioning and patient retention.

This pattern is consistent with the broader ACE inhibitor market experience and the general economics of mature small-molecule brands after exclusivity.

What is the financial trajectory to expect for VASOTEC revenues?

Core revenue math

Brand revenue is constrained by two levers:

• Net price declines with generic substitution and payer pressure.
• Share declines as prescribers and pharmacies switch to generics.

Absent renewed exclusivity (new chemical entity, meaningful reformulation with regulatory differentiation, or robust line extensions), the long-run outcome is:

• Declining unit share
• Accelerating revenue erosion as price cuts compound volume loss.

Business implications

• Marketing spend shifts from growth to defense: retention of the brand in specific formularies and physician segments rather than market expansion.
• Profit pool shrinks: gross margins compress as brand pricing moves closer to generic benchmarks.
• Portfolio rationalization: brands in mature therapeutic classes often face SKU pruning, channel rebalancing, and reduced promotional intensity.

What market dynamics are most relevant to ACE inhibitors like benazepril?

Pricing and substitution

• Therapeutic equivalence: Generics are bioequivalent, enabling direct substitution.
• Class-level competition: Multiple ACE inhibitors (and alternative classes such as ARBs) compete for the same prescribing intents.

Policy and payer design

• Formulary tiering: Tier reductions and preferred generic designations reduce brand conversion economics.
• Step edits and switching mandates: common in chronic cardiometabolic categories.

Competitive set behavior

• Generic multi-sourcing: once multiple manufacturers exist, price floors tend to stabilize at low levels, limiting upside for the originator brand.
• ARBs as alternative: payer preferences for specific ARBs can divert demand away from ACE inhibitors, depending on safety and guideline positioning.

Where does VASOTEC still hold value in the market?

VASOTEC can still sustain revenue in pockets where one or more factors persist:

• Institutional formularies that maintain brand options due to legacy contracts or procurement structures.
• Patient retention where switching is avoided for tolerability, adherence, or clinical inertia.
• Compliance and supply reliability considerations that favor established brand SKUs during supply disruptions in multi-source generic environments.

These pockets do not typically reverse long-run brand decline, but they can flatten the rate of sales erosion relative to markets with faster generic adoption.

What does the financial trajectory imply for investors and R&D strategy?

For investors

• Treat VASOTEC as a mature branded asset with returns increasingly driven by contracting and channel mix, not by innovation-led growth.
• The investment thesis typically depends on:
  • Extent of generic penetration by geography
  • Net price trajectory vs. generic competitors
  • Remaining formulary access and reimbursement stability.

For R&D and BD teams

• The benazepril brand case reinforces that incremental clinical differentiation without regulatory exclusivity rarely outperforms generics in mature classes.
• Strategic focus usually shifts to:
  • New indications with distinct endpoints
  • Novel formulations that qualify for meaningful regulatory differentiation
  • Combination products where exclusivity can be created through controlled clinical development pathways.

Key takeaways

• VASOTEC (benazepril) is a mature ACE inhibitor brand where long-run economics are dominated by generic substitution and payer steerage.
• Financial trajectory typically follows a post-exclusivity decline curve: net price erosion plus share loss.
• Residual brand value persists only in pockets tied to formularies, contracts, and patient retention, not through durable innovation economics.
• For investment and partnership decisions, VASOTEC should be treated as a defensive, contracting-driven revenue stream rather than a growth platform.

FAQs

1. Is VASOTEC expected to grow versus generics?
   In mature markets after generic entry, brand growth is structurally constrained; revenue trends typically decline unless supported by localized formulary and contracting advantages.

2. What most impacts VASOTEC net sales?
   Net price and prescription share versus generic benazepril, both driven by payer formulary position and switching behavior.

3. How does class competition affect VASOTEC?
   ACE inhibitor demand competes with ARBs and other antihypertensives; payer selection can shift share across classes.

4. Does remaining brand share indicate clinical advantage?
   Brand retention often reflects contracting and patient switching inertia rather than new clinical differentiation.

5. What is the usual strategic endpoint for mature ACE inhibitor brands?
   Maintenance of formulary access and margin defense, with limited upside absent regulatory exclusivity or differentiated product innovation.

References

1. FDA. Benazepril labeling (information for healthcare professionals). U.S. Food and Drug Administration.
2. DailyMed. VASOTEC (benazepril hydrochloride) prescribing information. U.S. National Library of Medicine.
3. FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations (benazepril products). U.S. Food and Drug Administration.